AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 161 min read$RCKT

Wilson Martin sold $256K of RCKT

Wilson Martin (General Counsel) sold 75,364 shares of ROCKET PHARMACEUTICALS, INC. (RCKT) at $3.40 ($0.26M total) on 2026-09-11.

Original reporting
SEC EDGAR · Wilson Martin
Published Sep 16, 2026, 12:27 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 12:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RCKT
Bearish
medium confidence
Mentioned
$RCKT
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RCKTBearishLow
01

Why it matters

The disclosed sale provides fresh data on insider sentiment but is modest in scale.

02

Market read

A small insider sale that may cause slight short‑term price pressure.

03

What to watch

Potential upcoming clinical trial data or partnership announcements that may offset the negative signal.

Relevance 4/10Novelty 3/10Timing: post‑market filing on 2026-09-11

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$RCKTBearishMedium confidence
Context

General Counsel Wilson Martin sold 75,364 shares of Rocket Pharmaceuticals for $256,463 on 2026-09-11.

Expected impact

Potential modest downward pressure on RCKT price in the short term.

Evidence & confidence

The sale size is small relative to holdings and market cap, so impact is likely limited.

Market effects

Sector

Minimal effect on biotech sector; insider sales are common and rarely move sector sentiment.

Regional

No regional impact beyond the company's own stock.

Global

Limited global relevance; only affects investors tracking RCKT.

Counterpoint

What could challenge this read

The sale could be unrelated to company prospects, e.g., personal liquidity needs.

Key entities

  • Company
    Rocket Pharmaceuticals, Inc.

    Biotech firm listed on NASDAQ under ticker RCKT.

  • Person
    Wilson Martin

    General Counsel of Rocket Pharmaceuticals.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RCKT insider trading history →

Related articles

SEP 23
$RCKTHighAI 8/10

Rocket Pharmaceuticals (RCKT) Gets FDA Alignment on Heart Drug Trial. Can it Ease Safety Concerns?

Rocket Pharmaceuticals (RCKT) announced FDA agreement to include 3 patients in its Phase 2 trial for Danon disease gene therapy RP-A501, with 9 more to be enrolled. The modified protocol includes dose adjustments and enhanced safety monitoring. The FDA confirmed 12-month co-primary endpoints for efficacy. The trial aims to complete dosing by mid-2027, with primary assessment 12 months post-treatment. Safety and efficacy data remain key uncertainties.

insidermonkey.com2 min
SEP 17
$RCKTMed

Refinancing all but vanishes as mortgage rates climb

Major U.S. mortgage lenders adjusted their 30-year fixed rates following the Federal Reserve's rate hike. Rocket Mortgage and Bank of America increased rates, while U.S. Bank lowered its. Freddie Mac reported a national average rate of 6.76%, with refinance applications dropping 9% week-over-week. Home-equity products saw increased interest, and the NAHB/Wells Fargo Housing Market Index fell to 32 in September.

aol.com3 min
SEP 16
$UNPMed

This Union Pacific Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Ulta Beauty (NASDAQ:ULT

Analysts upgraded several companies: Needham upgraded Similarweb (SMWB) to Buy with a $11 target, Wolfe Research upgraded Paychex (PAYX) to Peer Perform, Needham upgraded Rocket Pharmaceuticals (RCKT) to Buy with a $9 target, UBS upgraded Union Pacific (UNP) to Buy with a $339 target, and Barclays upgraded Alvotech (ALVO) to Overweight with a $8 target.

benzinga.com2 min
SEP 16
$RCKTHighAI 8/10

Rocket Pharmaceuticals’ FDA Decision Clears ‘Meaningful Regulatory Overhang,’ Says Needham — Sees 150% Upside Potential In RCKT Stock

Rocket Pharmaceuticals (RCKT) received an FDA alignment on a pivotal study for its genetic disease therapy, leading to a 'Buy' upgrade from Needham with a $9 price target, implying 150% upside. The FDA confirmed continued enrollment in the Phase 2 study of RP-A501 for Danon Disease, with dosing expected to complete by mid-2027. The stock was up 7.6% on the news.

stocktwits.com2 min
SEP 16
$RCKTHighAI 8/10

Needham Upgrades Rocket Pharmaceuticals (RCKT) to Buy After FDA

Needham upgraded Rocket Pharmaceuticals (RCKT) to Buy with a $9 price target after FDA approved the trial design for RP-A501, a gene therapy for Danon Disease. The FDA's modifications include dosing and patient inclusion criteria. RCKT has no revenue, a $375M market cap, and a GF Score of 25, indicating financial stability but operational challenges. Insiders sold $1.0M in shares over the past year, while institutional guru ownership remains steady.

gurufocus.com2 min